Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is FDA Reviewing A Biosimilar Marketing Application?

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency changes its rhetoric on the subject, inviting speculation about whether a marketing application has been received.

Advertisement

Related Content

Biosimilar Guidances Expected In ‘Near Future,’ But Unnecessary, FDA Says
Korea’s Celltrion, Partner Hospira Win Drug Procurement Bid In Norway For Infliximab Biosimilar
As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada
Naming Rights: Biosimilar Influence Efforts Continue Before Products Take The Field
Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?
Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
FDA Sets Biosimilar Application Fees, But Is Silent On Volume Projections

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel